Poltreg SA
WSE:PTG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Poltreg SA
Net Income (Common)
Poltreg SA
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Poltreg SA
WSE:PTG
|
Net Income (Common)
-zł18.7m
|
CAGR 3-Years
-71%
|
CAGR 5-Years
-81%
|
CAGR 10-Years
N/A
|
|
|
M
|
Marvipol Development SA
WSE:MVP
|
Net Income (Common)
zł58.2m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
M
|
MLP Group SA
WSE:MLG
|
Net Income (Common)
zł459m
|
CAGR 3-Years
3%
|
CAGR 5-Years
22%
|
CAGR 10-Years
20%
|
|
|
L
|
Lokum Deweloper SA
WSE:LKD
|
Net Income (Common)
zł33.4m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
0%
|
|
|
C
|
Captor Therapeutics SA
WSE:CTX
|
Net Income (Common)
-zł38.4m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
D
|
Develia SA
WSE:DVL
|
Net Income (Common)
zł443.5m
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
15%
|
|
Poltreg SA
Glance View
PolTREG SA develops and commercializes patented TREG methods. The company is headquartered in Gdansk, Woj. Pomorskie and currently employs 11 full-time employees. The company went IPO on 2021-11-23. The firm conducts research in the field of autoimmunological diseases. The firm works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The firm works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The firm is developing its own research center, which is intended as a basic location for conducting future research activities.
See Also
What is Poltreg SA's Net Income (Common)?
Net Income (Common)
-18.7m
PLN
Based on the financial report for Dec 31, 2024, Poltreg SA's Net Income (Common) amounts to -18.7m PLN.
What is Poltreg SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-81%
Over the last year, the Net Income (Common) growth was -38%. The average annual Net Income (Common) growth rates for Poltreg SA have been -71% over the past three years , -81% over the past five years .
